Mirror, Mirror: Long-acting Antibiotics Dalbavancin, Oritavancin Emerging With Similar Profiles
Executive Summary
Full results for Durata’s dalbavancin and The Medicine’s Co.’s oritavancin – both lipoglycopeptides – suggest the mode of administration is likely to become a key differentiating factor if the drugs are approved.
You may also be interested in...
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
Law has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
TMC Bets Dosing Convenience, Field Force Synergies Will Help Oritavancin Prosper
The Medicines Co. held an analyst meeting Oct. 9 in large measure to broadcast the progress it has made diversifying away from its current chief revenue generator, the cardiovascular drug Angiomax. It’s betting that its first foray into antibiotics, the IV-administered drug oritavancin, will best competition because of dosing advantages, efficacy, and the sponsor’s deep expertise in the tumultuous hospital market